WallStSmart

Merck & Company Inc (MRK)vsNeogen Corporation (NEOG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 7455% more annual revenue ($65.77B vs $870.56M). MRK leads profitability with a 13.6% profit margin vs -69.9%. NEOG appears more attractively valued with a PEG of 0.66. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

NEOG

Hold

41

out of 100

Grade: D

Growth: 4.0Profit: 2.0Value: 7.7Quality: 5.3
Piotroski: 3/9Altman Z: 0.07
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued
NEOGUndervalued (+81.3%)

Margin of Safety

+81.3%

Fair Value

$57.56

Current Price

$8.90

$48.66 discount

UndervaluedFair: $57.56Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

NEOG2 strengths · Avg: 9.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

PEG RatioValuation
0.668/10

Growing faster than its price suggests

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NEOG4 concerns · Avg: 2.5/10
Market CapQuality
$1.98B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-29.0%2/10

ROE of -29.0% — below average capital efficiency

Revenue GrowthGrowth
-4.4%2/10

Revenue declined 4.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : NEOG

The strongest argument for NEOG centers on Price/Book, PEG Ratio. PEG of 0.66 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : NEOG

The primary concerns for NEOG are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while NEOG is a turnaround play — different risk/reward profiles.

NEOG carries more volatility with a beta of 1.80 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 41/100). NEOG offers better value entry with a 81.3% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Neogen Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Neogen Corporation, develops, manufactures and markets various products for food and animal safety worldwide. The company is headquartered in Lansing, Michigan.

Visit Website →

Want to dig deeper into these stocks?